GlassScriptPhysician profile
Min Hyung Kim
NPI 1114296910
$6,450.17
in general payments reported to CMS, 2019-2025
39 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,708 · 2020: $1,420 · 2021: $863 · 2022: $401 · 2023: $266 · 2024: $326 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $814.43 | 2019-2025 | |
| Amarin Pharma, INC. | $665.80 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $604.82 | 2019-2022 | |
| Amgen INC. | $461.22 | 2019-2025 | Repatha, Otezla, Evenity |
| Radius Health, INC. | $439.80 | 2019-2023 | |
| Pfizer INC. | $369.27 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.71 | 2019-2025 | Jardiance |
| Scilex Pharmaceuticals INC. | $291.15 | 2019-2024 | Ztlido |
| Janssen Pharmaceuticals, INC | $249.20 | 2019-2022 | |
| Glaxosmithkline, LLC. | $246.10 | 2019-2021 | |
| Abbvie INC. | $240.54 | 2019-2025 | |
| Astellas Pharma US INC | $226.70 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $209.88 | 2019-2021 | |
| Shield Therapeutics INC | $196.24 | 2023-2025 | Accrufer |
| Gilead Sciences, INC. | $166.41 | 2019-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Hyung Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.